🚀 Big News from ProteinQure! 🚀 Exciting update: ProteinQure, has validated our lead program for triple-negative breast cancer (TNBC) and I'm thrilled to announce that our findings will be presented at the upcoming AACR conference in San Diego, showcasing our commitment to advancing cancer research (see press release for poster details). Our novel Peptide Drug Conjugate (PDC) has shown exceptional efficacy in battling TNBC, even in treatment-resistant cases. Performed at Dr. David Cescon's lab at Princess Margaret Cancer Centre/University Health Network, our PDC demonstrated remarkable results in over 15 heterogeneous Patient-Derived Xenograft (PDX) models. As a computational drug discovery company, it has been amazing to stop trying to convince people with benchmarks on irrelevant data sets and start pointing to multiple drug candidates that ProteinQure has enabled. We are looking forward to collaborating further with world-class clinicians on our Phase I clinical trial in the near future. I will be at AACR to learn from and speak to researchers about our development candidate and planned FIH trial. #ProteinQure #CancerResearch #AACR2024 #PrecisionMedicine #DrugDevelopment #AIDrugDiscovery https://lnkd.in/geZTFMtY
David Tart
6mo
Congrats Lucas!
Software Developer | UBC Instructor | Dormant Biologist
6moLove this!